Verve Therapeutics Inc (VERV) is lower by 11.57% Wednesday In Premarket Trading

Verve Therapeutics Inc (VERV) is lower by Wednesday morning, with the stock declining -11.57% in pre-market trading to 10.55. VERV's short-term technical score of 20 indicates that the stock has traded less bullishly over the last month than 80% of stocks on the market. In the Biotechnology industry, which ranks 128 out of 146 industries, Verve Therapeutics Inc ranks higher than 35% of stocks. Verve Therapeutics Inc has risen 34.95% over the past month, closing at $11.75 on November 1. During this period of time, the stock fell as low as $9.29 and as high as $20.12. VERV has an average analyst recommendation of Strong Buy. The company has an average price target of $43.67.

VERV has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on VERV!

See Full VERV Report

Verve Therapeutics Inc has a Long-Term Technical rank of 6. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 94% of the market scoring higher. In the Biotechnology industry which is number 130 by this metric, VERV ranks better than 130% of stocks.

Important Dates for Investors in VERV:

-Verve Therapeutics Inc is set to release earnings on 2024-02-05. Over the last 12 months, the company has reported EPS of $-3.09. -We do not have a set dividend date for Verve Therapeutics Inc at this time. Click Here To Get The Full Report on Verve Therapeutics Inc (VERV)